EFTReFFECTOR Therapeutics, Inc.

Nasdaq effector.com


$ 2.08 $ 0.03 (1.46 %)    

Wednesday, 08-May-2024 15:59:18 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 2.08
$ 2.06
$ 0.00 x 0
$ 2.10 x 400
$ 2.06 - $ 2.08
$ 1.60 - $ 37.00
118,184
na
4.55M
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-26-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-08-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-16-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 06-03-2021 03-31-2021 10-Q
13 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dow-dips-over-200-points-rpm-international-shares-fall-after-q3-results

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow...

 why-staar-surgical-shares-are-trading-higher-by-around-13-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...

 nasdaq-surges-1-conagra-brands-posts-upbeat-earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow ...

 cancer-focused-effector-therapeutics-shelves-development-of-lung-cancer-candidate-after-disappointing-data

eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib sh...

 dow-jumps-over-100-points-us-jobless-claims-increase-to-221000

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the marke...

 effector-therapeutics-announces-topline-results-of-phase-2-kickstart-trial-of-tomivosertib-combined-with-pembrolizumab-in-non-small-cell-lung-cancer

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) fo...

 hc-wainwright--co-reiterates-buy-on-effector-therapeutics-maintains-24-price-target

HC Wainwright & Co. analyst Robert Burns reiterates eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy and maintains $24 pri...

 effector-therapeutics-cash-cash-equivalents-and-short-term-investments-totaling-184m-as-of-december-31-2023-anticipates-that-it-will-be-sufficient-to-fund-operations-into-q1-of-2025

Fourth Quarter and Full Year 2023 Financial ResultsCash Position and Guidance: The company had cash, cash equivalents, and shor...

 effector-therapeutics-q4-eps-342-misses-165-estimate

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(3.42) per share which missed the analyst consensus estimate ...

 hc-wainwright--co-maintains-buy-on-effector-therapeutics-adjusts-price-target-to-24

HC Wainwright & Co. analyst Robert Burns maintains eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy, adjusts target to $24...

 effector-therapeutics-announces-15m-registered-direct-offering-priced-at-the-market-under-nasdaq-rules

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) (the "Company"), a leader in the development of selective translation regulat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION